DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting (PR Newswire)

DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting

UF startup DNAtrix, a leader in the development of oncolytic viruses for cancer therapy, presented updated safety and efficacy data from the fully-enrolled Phase 2 CAPTIVE / KEYNOTE-192 study of DNX-2401 (tasadenoturev), DNAtrix’s oncolytic adenovirus, followed by pembrolizumab for patients with recurrent glioblastoma. The data demonstrate that the therapy elicits durable clinical activity and has a favorable safety profile. These results were presented at the Society for Neuro-Oncology (SNO) Annual Meeting.

A total of 48 patients with recurrent glioblastoma were treated at 15 participating clinical sites with the regimen of DNX-2401, followed by pembrolizumab. The majority of patients experienced clinical benefit following treatment, including durable complete and partial responses. Interim median overall survival for patients is currently 12.3 months. In addition, the interim safety analysis demonstrates that the therapy has a positive benefit-risk profile, there were no unanticipated adverse events and patients remained on pembrolizumab for a median of 5.5 months with a maximum of 34 cycles.

Learn more about DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting.
X